Rare Diseases Today—July 9, 2026

This week’s Rare Diseases update highlights regulatory progress, clinical development, research collaboration, genomic innovation, and strategic investment across rare disease care.

In Today’s Newsletter

Dive deeper

💊 Neurocrine starts crinecerfont Phase 2 in classic CAH under age 4 [1] [US • 01 Jul 2026]

https://neurocrine.gcs-web.com/news-releases/news-release-details/neurocrine-biosciences-initiates-phase-2-study-crinecerfont
Context: The open-label, single-arm study will assess safety and tolerability over 24 weeks in 20 participants.
Key point: Neurocrine Biosciences initiated a Phase 2 study of crinecerfont in children aged 3 months to under 4 years with classic CAH.
Implication: May influence prescriber choice and payer reviews pending full data.

🌍 UK joins European Rare Diseases Research Alliance [2] [UK • 06 Jul 2026]

https://pharmaceutical-journal.com/article/news/uk-signs-up-to-european-rare-diseases-network
Context: ERDERA includes 37 countries and more than 170 public and private organisations.
Key point: The UK, through NIHR and DHSC, joined ERDERA to co-fund rare disease research calls.
Implication: Access programs may expand screening, initiation, and follow-up at scale.

🧬 South Korea MFDS adds rare disease regulatory support measures [3] [South Korea • 07 Jul 2026]

https://www.koreabiomed.com/news/articleView.html?idxno=32316
Context: Plans include patient experience data in reviews and guidance for rare disease cell and gene therapy development.
Key point: MFDS announced medical product initiatives to support biopharma and rare disease care.
Implication: Signals pipeline investment and modality expansion.

🧪 EVE platform accelerates rare endocrine disorder variant analysis [4] [South Korea • 07 Jul 2026]

https://www.koreabiomed.com/news/articleViewAmp.html?idxno=32341
Context: EVE focuses on 413 endocrine disorder genes and generated clinician-friendly reports in validation work.
Key point: Gachon University Gil Medical Center and Korea University developed EVE for rare endocrine disorder variant filtering.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🧠 Vanda gains FDA rare pediatric designation for VCA-894A in CMT2S [5] [US • 07 Jul 2026]

https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-fda-rare-pediatric-disease-designation-for-investigational-therapy-for-charcot-marie-tooth-disease-type-2s-302819555.html
Context: VCA-894A is an investigational antisense oligonucleotide therapy targeting a unique CMT2S variant.
Key point: FDA granted Rare Pediatric Disease Designation to Vanda’s VCA-894A for Charcot-Marie-Tooth disease type 2S.
Implication: Regulatory designation may support future review incentives if statutory requirements are met.

📄 Saol resubmits SL1009 NDA for PDCD [6] [US • 07 Jul 2026]

https://www.prnewswire.com/news-releases/saol-therapeutics-resubmits-the-new-drug-application-for-sl1009-dca-for-the-treatment-of-pyruvate-dehydrogenase-complex-deficiency-pdcd-an-ultra-rare-disease-302816217.html
Context: The resubmission followed FDA meetings and additional analyses of existing data after an August 2025 CRL.
Key point: Saol Therapeutics resubmitted the NDA for SL1009 (sodium dichloroacetate) in PDCD.
Implication: Regulatory progress may affect treatment access pending FDA acceptance and review.

🤝 Vertex acquires Crinetics for endocrine rare disease pipeline [7] [US • 07 Jul 2026]

https://www.fiercepharma.com/pharma/vertex-acquires-endocrine-disease-specialist-crinetics-10b
Context: The deal adds Palsonify for acromegaly and atumelnant, an investigational ACTH receptor antagonist for CAH and Cushing syndrome.
Key point: Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $10 billion.
Implication: Signals pipeline investment and modality expansion.

Why it matters

Pediatric rare endocrine disease remains a focus, with Neurocrine and Crinetics-linked assets targeting classic CAH.
Regulatory agencies are emphasizing rare disease flexibility, patient experience data, and international trial networks.
Genomic tools such as EVE may reduce diagnostic workload for rare endocrine disorders.
FDA designations and NDA resubmissions show continued activity in ultra-rare pediatric and mitochondrial diseases.
Vertex’s Crinetics deal adds scale to endocrine rare disease commercialization and late-stage development.

📚 View the full Rare Disease archive on our research hub page

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

FAQ

What is crinecerfont being studied for by Neurocrine Biosciences?

Neurocrine initiated a Phase 2 study of crinecerfont in children aged 3 months to under 4 years with classic CAH. The study focuses on safety and tolerability. [1]

What does UK participation in ERDERA change for rare disease research?

NIHR said UK participation opens pathways for UK researchers to join international rare disease studies and clinical trials. [2]

How is South Korea’s MFDS changing rare disease reviews?

MFDS plans to allow patient surveys, interview transcripts, and other patient experience data in certain reviews, including serious and rare disease medicines. [3]

What does EVE do for rare endocrine disorders?

EVE is a genomic analysis platform that filters whole-exome sequencing data across endocrine disorder genes and produces clinician-friendly reports. [4]

What is Vanda’s VCA-894A?

VCA-894A is an investigational antisense oligonucleotide therapy for CMT2S, a rare inherited neuromuscular disorder. FDA granted it Rare Pediatric Disease Designation. [5]

What is Vertex gaining from Crinetics?

Vertex is acquiring Crinetics’ endocrine portfolio, including Palsonify for acromegaly and atumelnant for CAH and Cushing syndrome development. [7]

Entities / Keywords

Neurocrine Biosciences, crinecerfont, CRENESSITY, classic congenital adrenal hyperplasia, CAH, pediatric CAH
UK NIHR, DHSC, ERDERA, European Rare Diseases Research Alliance, rare disease clinical trials
South Korea MFDS, patient experience data, rare disease review, cell and gene therapy, essential medicines
Gachon University Gil Medical Center, Korea University, EVE, Endocrine Variant Extractor, rare endocrine disorders, GATA3, HDR syndrome
Vanda Pharmaceuticals, VCA-894A, antisense oligonucleotide, Charcot-Marie-Tooth disease type 2S, CMT2S, Rare Pediatric Disease Designation
Saol Therapeutics, SL1009, sodium dichloroacetate, DCA, pyruvate dehydrogenase complex deficiency, PDCD, NDA resubmission
Vertex Pharmaceuticals, Crinetics Pharmaceuticals, Palsonify, atumelnant, ACTH receptor antagonist, acromegaly, Cushing syndrome